



(43) International Publication Date  
20 March 2014 (20.03.2014)

(10) International Publication Number  
**WO 2014/041425 A1**

(51) International Patent Classification:

A61K 38/12 (2006.01) A61K 31/19 (2006.01)  
A61K 9/19 (2006.01) A61K 31/7008 (2006.01)  
A61K 31/375 (2006.01)

(21) International Application Number:

PCT/IB2013/002191

(22) International Filing Date:

11 September 2013 (11.09.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/699,570 11 September 2012 (11.09.2012) US  
61/839,699 26 June 2013 (26.06.2013) US

(71) Applicant: **HOSPIRA AUSTRALIA PTY LTD.**  
[AU/AU]; A.c.n. 097064330, 1 Lexia Place, Mulgrave  
North, Victoria, 3170 (AU).

(72) Inventor: **ALEXIOU, Jim**; 7 Turnbull Avenue, Oakleigh  
East, Victoria, 3166 (AU).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,  
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,  
ZW.

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: DAPTOMYCIN FORMULATIONS AND USES THEREOF

(57) Abstract: Lyophilized daptomycin formulations having improved reconstitution times are provided. The lyophilized daptomycin formulations include an additive, which can be a pharmaceutically acceptable antioxidant, a pharmaceutically acceptable organic acid or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable glucose derivative or a pharmaceutically acceptable salt thereof, or a combination thereof. Also provided are methods of preparing the lyophilized daptomycin formulations, and methods of treating bacterial infections and treating or preventing biofilms by using the lyophilized daptomycin formulations.



WO 2014/041425 A1